Pancreatic carcinoma is one of the most aggressive tumors, and, being refractory to conventional therapies, is an excellent target for new therapeutic approaches. Based on our previous finding of high HMGA1 expression in pancreatic cancer cells compared to normal pancreatic tissue, we evaluated whether suppression of HMGA1 protein expression could be a treatment option for patients affected by pancreatic cancer. Here we report that HMGA1 proteins are overexpressed in pancreatic carcinoma cell lines, and their downregulation through an adenovirus carrying the HMGA1 gene in an antisense orientation (Ad Yas-GFP) results in the death of three human pancreatic carcinoma cell lines (PANC1, Hs766T and PSN1). Pretreatment of PANC1 and PSN1 cells with Ad Yas-GFP suppressed and reduced, respectively, their ability to form xenograft tumors in nude mice. To further verify the role of HMGA1 in pancreatic tumorigenesis, we used a HMGA1 antisense phosphorothioate oligodeoxynucleotide (ODN); its addition induced a decrease in HMGA1 protein levels and a significant reduction of the proliferation rate of PANC1-, Hs766T-and PSN1-treated cells. Therefore, suppression of HMGA1 protein synthesis by an HMGA1 antisense approach seems to be a feasible treatment strategy in pancreatic carcinomas. Cancer Gene Therapy ( Keywords: HMGA1; pancreatic carcinoma; adenovirus; apoptosis P ancreatic cancer is the fifth leading cause of cancer death in the United States; it presents its symptoms late in the course of the disease and is usually fatal within a year. In fact, the 5-year survival rate of pancreatic cancers (85% of which is of ductal cell origin) is only 1.3%, which is the lowest of more than 60 cancer sites reviewed. Pancreatic cancer is refractory to radiation and chemotherapy, and complete surgical resection is the only therapeutic option; however, only 5% of tumors are resectable at the time of diagnosis. In addition, for all stages of surgically resectable disease combined, the overall 5-year survival is less than 15% of cases.
P
ancreatic cancer is the fifth leading cause of cancer death in the United States; it presents its symptoms late in the course of the disease and is usually fatal within a year. In fact, the 5-year survival rate of pancreatic cancers (85% of which is of ductal cell origin) is only 1.3%, which is the lowest of more than 60 cancer sites reviewed. Pancreatic cancer is refractory to radiation and chemotherapy, and complete surgical resection is the only therapeutic option; however, only 5% of tumors are resectable at the time of diagnosis. In addition, for all stages of surgically resectable disease combined, the overall 5-year survival is less than 15% of cases. [1] [2] [3] Therefore, alternative therapeutic strategies are urgently required for pancreatic cancer. The aim of our study was to evaluate whether suppression of HMGA1 protein synthesis with an adenoviral vector could benefit patients with pancreatic cancer.
The HMGA family consists of three proteins: HMGA1a, HMGA1b and HMGA2. The former two, which differ from each other by 11 amino acids, are generated by the same functional gene, whereas HMGA2 is the product of a separate gene. [4] [5] [6] HMGA proteins play key roles in chromatin architecture and gene control. It has been suggested that they do so by serving as generalized chromatin effectors, either enhancing or suppressing the ability of other transcriptional activators and repressors to act within the confines of chromatinized DNA. [7] [8] [9] HMGA1 proteins are abundantly expressed during embryogenesis. In contrast, they are expressed at very low levels in normal adult rodent and human tissues; 10, 11 this indicates that the HMGA1 proteins are critical for cell proliferation and/or differentiation during normal development. High HMGA1 protein expression is associated with many human neoplasms originating from a variety of tissues. [12] [13] [14] [15] [16] [17] [18] [19] We previously reported a significant correlation between overexpression of the HMGA1 proteins and pancreatic cell carcinoma. 18 This report indicated that increased HMGA1 protein expression is closely associated with the malignant phenotype in the pancreas, as has been observed in other human malignancies.
The finding that blockage of HMGA1 protein synthesis by an antisense methodology prevents their neoplastic transformation by murine acute retroviruses shows that HMGA1 protein synthesis is required for cell transformation in vivo. 20, 21 Moreover, rat fibroblasts overexpressing HMGA1 form tumors and distant metastases in nude mice, 22 and transgenic mice overexpressing the HMGA1 gene develop NK lymphomas 23 and pituitary adenomas. 24 We recently generated an adenovirus carrying the HMGA1 gene in an antisense orientation. This virus (Ad Yas) induced the death of two human thyroid anaplastic carcinoma cell lines (ARO and FB-1), but not of normal thyroid cells. 25 Taken together, these data suggest that suppression of HMGA proteins with the antisense technique might be envisaged as a treatment strategy for human malignant neoplasias. Moreover, the low or null HMGA gene expression in normal adult tissues suggests that this gene therapy would have a high specificity and low toxicity.
To verify this hypothesis we infected three pancreatic carcinoma cell lines (PANC1, Hs766T and PSN1), which overexpress HMGA1 proteins, with the adenovirus Ad Yas-GFP carrying the HMGA1 sequence in an antisense orientation. All three cell lines died after infection. In contrast, infection with the same adenoviral vector carrying only the GFP gene had no effect. We also demonstrate that the injection of PANC1 and PSN1 preadsorbed with Ad Yas-GFP suppresses and reduces, respectively, the growth of xenograft tumors in nude mice. Finally, we show that an HMGA1 antisense phosphorothioate oligodeoxynucleotide (ODN) reduces HMGA1 protein levels and in vitro cell proliferation.
Materials and methods

Cell lines
Human pancreatic cancer cell lines: AsPC1, BxPC3, PANC1, Hs766T, Capan 2, MiaPaca and CFPAC were obtained from American Type Culture Collection (ATCC, Manassas, VA); PSN1 cells were from the European Collection of Cell Cultures (ECACC, Salisbury, UK). The ARO cell line derives from a human thyroid anaplastic carcinoma. 25 All cells were grown in RPMI containing 10% fetal calf serum. Human embryonic kidney cells (HEK293) were purchased from Microbix Biosystem (Toronto, Canada); they were grown in DMEM plus 10% fetal bovine serum and used for adenovirus packaging and amplification. Cells were maintained at 371C in a humidified atmosphere of 5% CO 2 in the corresponding growth medium with supplements added as recommended.
Preparation of the recombinant adenoviruses
Vectors were constructed according to the manufacturer's instructions (QBiogene, Carlsbad, CA). The HMGA1 cDNA was inserted in an antisense orientation into the Adeno-Quest Transfer vector designated pQBI-AdBM5-GFP. In this transfer vector, the HMGA1 cDNA is controlled by the modified adenoviral major late promoter (MLP), whereas the green fluorescent protein (GFP) expression is controlled by a cytomegalovirus (CMV) promoter. This arrangement allows for easy visualization of the transduced cells and maximal expression levels with a lower multiplicity of infection (MOI). An adenovirus carrying GFP under the transcriptional control of a CMV promoter (Ad GFP) served as a control (Qbiogene, Carlsbad, CA).
In vitro transduction
Pancreatic cancer cells were transduced with adenoviral vectors by directly applying the diluted vectors into the growth medium. Cells were transduced with either Ad GFP or the Ad Yas-GFP viral construct at MOI 50. To determine transduction efficiency, we used fluorescence microscopy to measure the proportion of GFP-expressing cells after Ad GFP and Ad Yas-GFP transduction.
Reverse transcriptase-PCR analysis
RNAs from wild-type and virally transduced PANC1, Hs766T and PSN1 were extracted by using Trireagent (Molecular Research Center, Cincinnati, OH) following the manufacturer's instructions. In all, 2 mg of total RNA was reverse transcribed and amplified with mouse RT-PCR samples were loaded on a 1.0% agarose gel for electrophoresis and stained with ethidium bromide. A specific human b-actin fragment was amplified to normalize the samples.
Immunoblotting analysis
Cells were washed once in cold phosphate-buffered saline (PBS) and lysed in a buffer containing 50 mM N-2-hydroxyethylpiperazine-N 0 -2-ethanesulfonic acid (HEPES; pH 7.5), 1% (v/v) Triton X-100; 50 mM NaCl; 5 mM EGTA, 50 mM NaF; 20 mM sodium pyrophosphate; 1 mM sodium vanadate, 2 mM phenylmethylsulfonyl fluoride, and 5 mg each of aprotinin and leupeptin per ml. Lysates were clarified by centrifugation at 10,000 g for 15 minutes, and the supernatant was stored at À701C. Protein concentration was calculated with a modified Bradford assay (Bio-Rad, Hercules, CA). Total proteins (50 mg) were separated by 15% SDS-PAGE and transferred to PVDF membranes (Immobilon-P Millipore, Bedford, MA). Membranes were blocked with 5% nonfat milk proteins and incubated with rabbit polyclonal antibodies raised against a synthetic peptide located in the NH 2 terminal region of the HMGA1 proteins 12 at a dilution of 1:1000. Bound antibodies were detected by a secondary anti-rabbit HRP-conjugated antibody (Santa Cruz Biotechnology, Santa Cruz, CA) and revealed with the Amersham ECL system (Amersham, Piscataway, NJ). Antibodies against b-actin and g-tubulin were purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
Assessment of in vitro cell death
Cells were transduced with Ad Yas-GFP, Ad GFP or mock transduced with PBS and harvested at different time points after transduction. To determine the percentage of dead cells, cells were stained with 0.2% trypan blue and counted with a hemocytometer. As a measurement of the fraction of apoptotic cells, the percentage of hypodiploid cells was determined by FACS analysis after staining cells with propidium iodide. Standard protocols were used for flow cytometry. 26 
Tumorigenicity assay
All experiments were conducted with 6-week-old male athymic mice (Charles-River, Wilmington, MA). PANC1 cells (1 Â 10 6 ) untreated, or previously transduced with either Ad Yas-GFP or Ad GFP at MOI 50, were injected into the flank of athymic mice. Another group of animals was subcutaneously injected with PSN1 cells (1x10 6 ) treated as described above. Mice were killed 30 days after inoculation, and tumor volumes were assessed. Tumor volumes (V) were calculated with the rotational ellipsoid formula:
No mouse showed signs of wasting or other signs of toxicity. All mice were maintained at the Kimmel Cancer Center Animal Facility and all animal studies were conducted in accordance with the international regulations for experimentations on animals.
Antisense ODNs experiments
Antisense oligonucleotides have been designed and synthesized specifically for the modulation of HMGA1 expression by BIOGNOSTIK (Go¨ttingen, Germany) according to the NCBI gene accession number NM_002131. The used control oligonucleotide is of the same length with the same proportion of the four base pairs, but randomly organized. Phosphorothioate oligonucleotides were used to ensure sufficient stability against intracellular DNAses. Oligonucleotides were added once at a concentration of 2 mM and cells were counted on a regular base. The presence of the oligonucleotides was proven by microscopically detecting fluorescence-labeled oligonucleotides.
Results
Generation of an adenoviral vector carrying the HMGA1 gene in an antisense orientation and the GFP
We generated an adenoviral vector that, besides the specific transgene expressed in our previous vector, 25 also expresses the reporter GFP protein in virally transduced cells. Thus, the mouse HMGA1 coding sequence was inserted in antisense orientation into the transfer vector pQBI-AdBM5 (Qbiogene, Carlsbad, CA) under the transcriptional control of the modified adenoviral MLP promoter; an independent CMV promoter in the same vector drives the GFP expression in transduced cells (Fig  1) . This arrangement allows for easy visualization of the transduced cells by fluorescence microscopy and maximal expression levels with lower MOI values.
HMGA1 expression in pancreatic carcinoma cell lines, and suppression of HMGA1 protein synthesis by infection with Ad Yas-GFP We first examined HMGA1 protein expression in eight pancreatic carcinoma cell lines (AsPC1, MIAPACA, Hs766T, BxPC3, Capan2, PSN1, PANC1 and CFPAC). Figure 2 , all cell lines expressed HMGA1 protein, whereas no expression was detected in normal pancreas (ProSci Inc., Poway, CA); this agrees with findings obtained with tumor specimens.
18 HMGA1 expression was highest in PANC1 and Hs766T cells. As a negative control, we used human normal thyroid tissue that, as reported elsewhere, 12, 15 did not express HMGA1. An anaplastic thyroid carcinoma cell line served as a control. 25 We next examined the effect of Ad Yas-GFP on the PANC1, Hs766T and PSN1 cell lines that originate from human epithelial pancreatic carcinomas and express high HMGA1 levels (Fig 2) . Direct fluorescence experiments showed that the virus infected these cells (data not shown). The transduction efficiency at MOI 50 was approximately 100% in PANC1, 60% in Hs766T and 30% in PSN1 cells.
To assess the expression of the exogenous HMGA1 sequence in PANC1, Hs776T and PSN1 cells infected with Ad Yas-GFP, an RT-PCR analysis was performed with primers designed on the mouse HMGA1 sequence carried by the adenovirus that were unable to amplify the human endogenous messenger. As shown in Figure 3a , exogenous HMGA1 was detected in Ad Yas-GFP-infected cells, whereas no amplification was observed in mock-infected cells and cells infected with an Ad GFP. No product of amplification was detected after PCR of nonretrotranscribed RNAs (data not shown).
The Western blot analysis showed that HMGA1 protein levels were dramatically reduced in the pancreatic carcinoma cell lines infected with Ad Yas-GFP (Fig 3b) . Conversely, HMGA protein levels in the control infected cells were similar to those in the uninfected pancreatic carcinoma cell lines. b-actin and g-tubulin protein levels were unchanged in cell lines infected with the same adenoviruses, thereby demonstrating equal protein loading and absence of nonspecific inhibition of protein synthesis in the infected cells.
Cytotoxic effect of Ad Yas-GFP on neoplastic cells
To study the effect of Ad Yas-GFP on pancreatic carcinoma cell growth, we plated the PANC1, Hs766T and PSN1 carcinoma cell lines (50,000/well), and next day exposed them to either Ad Yas-GFP or Ad GFP at MOI 50. Treated cells were harvested daily for cell counting. As shown in Figure 4 , infection of the pancreatic carcinoma cells with the Ad Yas-GFP virus significantly reduced the cell number over the 4 days examined. infected at MOI 50 dramatically increased proportionally to their susceptibility to the adenoviral infection, as described above. Conversely, there were no changes in the cell cycle profile in either uninfected or Ad GFPinfected cells (Fig 5) . A TUNEL assay confirmed that most of the cells in sub-G1 underwent apoptosis (data not shown). Gene therapy of pancreatic cancer blocking HMGA1 F Trapasso et al
Suppression of PANC1 and PSN1 cell line tumorigenicity by the Ad Yas-GFP virus
To evaluate the potential of Ad Yas-GFP to inhibit the in vivo tumor formation of pancreatic cells, PANC1 and PSN1 were preadsorbed with either Ad Yas-GFP (MOI 50) or Ad GFP (MOI 50) and then injected 24 hours after infection into athymic mice. Mice were monitored for 30 days and then killed. No tumors appeared when PANC1 cells were preinfected with Ad Yas-GFP (Fig 6) . Conversely, all the athymic mice injected with the untreated PANC1 cells and those treated with the control Ad GFP virus developed tumors ranging between 0.7 and 0.9 cm 3 at the inoculation site. PSN1 cells transduced with Ad Yas-GFP still produced tumors but they were significantly smaller than those in the uninfected and Ad GFP-infected controls (1 versus 3 cm 3 ) (Fig 6) .
Antiproliferative effect of a specific HMGA1 antisense oligonucleotide
To confirm the specificity of the effects described in malignant pancreatic cells after their infection with Ad Yas-GFP, we used an antisense oligonucleotide directed against the human HMGA1 coding sequence. At 48 hours after a single addition, a significant reduction of the HMGA1 protein expression levels was detected in PANC1, Hs766T and PSN1 cells; no changes were observed in cells treated with a control ODN (Fig 7) . To evaluate the effects of such a protein reduction on cell proliferation, we performed a growth curve by plating 1 Â 10 4 cells per well in a 24-well plate. Untreated cells and cells treated either with a control ODN or an HMGA1 antisense ODN 1 hour after seeding were counted every 24 hours for a period of 4 days. As shown in Figure 8 , the number of cells treated with the specific HMGA1 ODN was significantly reduced compared to both wild-type and control ODN-treated cells.
Discussion
Ductal pancreatic adenocarcinoma represents 80-85% of all pancreatic malignancies and is one of the most lethal cancers in the Western world. Despite recent advances in diagnostics, staging and therapy, the long-term survival of patients remains dismal. In fact, pancreatic carcinoma is refractory to chemotherapy and radiotherapy. [1] [2] [3] Inactivation of p53, a constant feature of pancreatic carcino- Gene therapy of pancreatic cancer blocking HMGA1 F Trapasso et al ma, 27, 28 could account for resistance to therapy. In fact, p53 function is required for growth arrest or apoptosis after administration of DNA-damaging agents.
New approaches to pancreatic cancer come from recent molecular technologies that either specifically target malignant cells by interfering with their signal transduction pathways or target the tumor microenvironment. Promising targets within the tumor microenvironment are the matrix metalloproteinases (MMP), which are overexpressed by epithelial pancreatic malignant cells; Marimstat, an MMP inhibitor, suppressed MMP in a clinical trial of patient with inoperable pancreatic cancer. 29 Other microenvironmental targets are the pathways leading to angiogenesis, a crucial event for primary tumor growth and its metastases, due to upregulation of vascular endothelial growth factor. 30 Other approaches are based on signal transduction inhibition. Several protooncogenes and tumor suppressor genes have been implicated in pancreatic tumors. 31 The K-ras pathway is one of the pathways most frequently involved in these tumors; however, even though previous studies showed that inhibitors that block ras farnesylation were effective in preclinical in vitro and in vivo models of pancreatic cancer, no significant activity was demonstrated in early clinical trials. 32 The gene therapy of pancreatic cancer through the viral transduction of molecules in malignant cells seems to be a way to act on molecularly unbalanced pathways. In fact, this approach has been successfully applied in both in vitro and in vivo preclinical models by transducing the missing genes p53, p16INK4a, p21WAF1 and FHIT. [33] [34] [35] [36] Another approach is to neutralize overexpressed oncogenes in malignant pancreatic cells, as in the case of H-ras blocked by an adenovirally transduced dominant-negative H-ras mutant. 37 In this study, we evaluated the efficacy of pancreatic cancer gene therapy based on suppression of HMGA1 protein synthesis. The rationale for this approach came from previous results showing that: (1) HMGA1 protein is overexpressed in pancreatic carcinoma but not in the pancreatic normal tissue; 18 (2) HMGA overexpression is crucial for neoplastic transformation since its block prevents thyroid cell transformation induced by the viral k-ras oncogene; 20,21 (3) that K-ras activation is an early and very frequent finding in ductal pancreatic carcinomas 38 and (4) that an adenovirus carrying the HMGA1 in an antisense orientation leads to the death of thyroid carcinoma cell lines, but not of normal thyroid cells that do not express the HMGA1 proteins. 25 The results reported herein show that gene therapy based on blocking HMGA1 protein synthesis is a feasible option in pancreatic cancer. In fact, the adenovirus carrying the HMGA1 sequences in an antisense orientation suppressed HMGA1 protein synthesis, and inhibited the growth of pancreatic carcinoma cells. We also show that Ad Yas-GFP treatment drastically reduced the growth of xenograft tumors induced in athymic mice by the injection of PANC1 and PSN1 cells.
Obviously, this therapeutic approach could be combined with conventional therapy. Therefore, studies are underway in our laboratory to evaluate whether Ad Yas-GFP and antineoplastic drugs such as gemcitabine, 29, 39 the current first line therapy for advanced pancreatic cancer, act synergistically to induce the death of pancreatic cells. Similarly, Ad Yas treatment could be associated with other forms of gene therapy such as the ONYX-015 virus that selectively kills cells carrying an inactivated p53 gene 40 or with HD-AdE2F1 that overexpresses the E2F1 transcription factor and that, alone or synergistically with gemcitabine, induces apoptosis in pancreatic carcinoma cell lines. 41 Expression of long antisense sequences may include the possibility of alteration of nonspecific targets in addition to the desired target; in fact, in most of mammalian cells they can induce the antiviral interferon (IFN) response. 42 Instead, small antisense sequences (21-28 nucleotides in length) can effectively reduce gene expression in many mammalian cells types without triggering the IFN response. [43] [44] [45] To overrule the possibility of a toxic Figure 8 Growth inhibitory effect of an HMGA1 antisense oligonucleotide (ODN) on pancreatic carcinoma cells. PANC1, H766T and PSN1 cells were plated (10,000/well) and 1 hour later they were exposed to 2 mM of either a control ODN or an HMGA1 antisense ODN. Cells were harvested daily for cell counts. The figure is representative of three different experiments (7SD).
Gene therapy of pancreatic cancer blocking HMGA1 F Trapasso et al nonspecific effect on pancreatic malignant cells due to the expression of a long antisense driven by a recombinant adenovirus, we also used a small HMGA1 antisense oligonucleotide that resulted in both HMGA1 protein downregulation and suppression of cell growth. Taken together, these data indicate that the suppression of HMGA1 protein synthesis is a new and promising approach to the treatment of human pancreatic cancer.
